Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety and pharmacokinetics after administration of NVP-2203.
Phase 1 to evaluate the safety and pharmacokinetics after administration of NVP-2203.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NVP-2203 | Experimental | After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2) |
|
| NVP-2203-R | Active Comparator | After fasting (except water) for at least 10 hours before dosing, oral administration of investigational product once daily on Period 1(or Period 2) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NVP-2203 | Drug | NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| NVP-2203's pharmacokinetics of plasma | AUCt | 0hours - 72hours |
| Measure | Description | Time Frame |
|---|---|---|
| pharmacokinetics of plasma | Cmax | 0hours - 72hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jaewoo Kim | H Plus Yangji Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| H Plus Yangji Hospital | Seoul | Nambusunhwan-ro | 08779 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| NVP-2203-R |
| Drug |
administration of active comparator |
|